SCHEMBL6094559

SCHEMBL6094559

O=C(c1ccc2[nH]ccc2c1)N1CCN(c2ccc(Cl)s2)CC1

nearest known ligand 0.56

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 2/20 0.56
MGLL Q99685 1/20 0.52
GPR183 P32249 1/20 0.50
DRD2 P14416 1/20 0.48
DRD3 P35462 1/20 0.48
FASN P49327 1/20 0.47
GHSR Q92847 2/20 0.47
CCR3 P51677 1/20 0.46
NUDT15 Q9NV35 1/20 0.46
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
RECQL P46063 1/20 0.44
KDM4E B2RXH2 1/20 0.44
SLC6A7 Q99884 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6096974 0.92 GHSR (0.57) MAPK14MGLLGHSRGAAMAPT
Hydrochloric Acid SCHEMBL27574061 0.91 GHSR (0.56) MAPK14MGLLGHSRGAAMAPT
SCHEMBL6098930 0.84 MAPK14 (0.56) MAPK14MGLLGPR183DRD2DRD3
SCHEMBL6093818 0.81 MAPK14 (0.57) MAPK14MGLLGPR183DRD2DRD3
SCHEMBL6096172 0.80 MAPK14 (0.60) MAPK14MGLLGPR183DRD2DRD3
SCHEMBL6096167 0.80 MAPK14 (0.52) MAPK14MGLLGPR183DRD2DRD3
SCHEMBL30329646 0.77 MAPK14 (0.64) MAPK14MGLLGPR183DRD2DRD3
SCHEMBL22216445 0.77 MAPK14 (0.64) MAPK14MGLLGPR183DRD2DRD3
SCHEMBL30226931 0.77 MAPK14 (0.64) MAPK14MGLLGPR183DRD2DRD3
SCHEMBL8534513 0.77 MAPK14 (0.64) MAPK14MGLLGPR183DRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7084143-B2 N-(indolecarbonyl) piperazine derivatives MERCK PATENT GMBH (DE) 2006-08-01 US claimed
US-6838461-B1 N-(indolcarbonyl-)piperazine derivatives MERCK PATENT GMBH (DE) 2005-01-04 US claimed
US-20050096330-A1 N-(indolecarbonyl) piperazine derivatives BOETTCHER HENNING (DE) 2005-05-05 US disclosed
CN-1364157-A N-(indolcarbonyl) piperazin derivatives MERCK PATENT GMBH (DE) 2002-08-14 CN disclosed
EP-1198453-A2 N-(INDOLCARBONYL-)PIPERAZIN DERIVATIVES MERCK PATENT GmbH (DE) 2002-04-24 EP disclosed
WO-2001007435-A2 N-(INDOLCARBONYL-)PIPERAZIN DERIVATIVES ALS 5-HT2A-RECEPTOR LIGANDS MERCK PATENT GMBH (DE) 2001-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096330-A1 N-(indolecarbonyl) piperazine derivatives HTR2A, HTR2B, HTR2C MAPK14 4409/4885MGLL 2125/4885GPR183 485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.